TrialJournal for immunotherapy of cancer2022

Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Benny Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.